BCL2L11 and chronic myelogenous leukemia, BCR-ABL1 positive: Our results demonstrate that SB939 overcomes BIM deletion polymorphism-induced TKI resistance, and suggest that SB939 may be useful in treating CML patients with BIM deletion-associated TKI resistance.